The domestic business has registered a single-digit growth on the huge base of last year and this was driven by robust demand across established therapies and brands
Aarti Drugs Limited has reported total income of Rs. 622.22 crores during the quarter ended June 30, 2022.
Company raises the annual revenue guidance from mid-teens to high teens
Glenmark Pharmaceuticals announced its financial results for the fourth quarter ended March 31, 2022
Ind-Ra expects FY22 IPM to have witnessed 15% YoY sales growth, higher than the 8%-10% observed over the past five years, aided by the base effect
Company expects strong organic growth in sales, EBITDA in 2022
The company has reported total income of Rs. 3715.8 crores during the quarter ended December 31, 2021
Contribution from the top five therapies stood at 58% of IPM in October 2021. These therapies are cardiac, anti-infectives, gastro-intestinal, anti-diabetic and vitamins
The Research Services and Biosimilars business segments reported a growth of 17% and 10%, respectively
Key takeaways of recent quarter & conference call highlights
Subscribe To Our Newsletter & Stay Updated
